Shares of Vivus Inc. tumbled 16 percent Thursday in premarket trading a day after the drug developer released data linking an ingredient in a weight loss treatment it is developing to an increased risk of birth defects.
Popular Posts:
- Inhibitex shares sink after drug trial announced
- FDA declines to approve Alimera’s eye drug, shares tank
- Biotech Firm Mesoblast Shares Soar 27% on M&A Buzz
- Ahead of the Bell: Endo Pharma share price rises
- Olympus delays earnings announcement; shares plunge